Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Tuberculosis (TB) is an ancient and complex human illness that we now know exists as a disease spectrum resulting from a dynamic interaction between the host immune system and the bacilli. Aside from COVID-19, TB is the leading cause of global morbidity and mortality from a single infectious disease agent. *Mycobacterium tuberculosis* (*Mtb*), the etiological agent of TB disease in humans, latently infects approximately one-fourth of the world’s population and kills approximately 1.5 million individuals a year (WHO, 2018).

To break the cycle of our ongoing failure to control TB globally, new tools—particularly vaccines—are desperately needed. In stark contrast to the breakneck speed with which three vaccines for COVID-19 were developed and approved in under 1 year, 2021 marks the 100th anniversary of the only existing TB vaccine, BCG—a vaccine that despite near global use for many decades does not alone control TB. The basis of this failure to identify an effective vaccine for TB is our incomplete understanding of immunologic correlates of protection. To proceed rationally, vaccine developers need an improved understanding of what immunity to TB looks like; essentially immunologic goalposts of what to aim for remain urgently needed.

In this issue of *Cell Host & Microbe*, Esaulova et al. reveal cell types associated with TB containment and disease progression in non-human primates, which may provide immunologic goalposts for vaccine design.

A limiting factor in identifying effective tuberculosis (TB) vaccines is our incomplete understanding of correlates of protection. In this issue of *Cell Host & Microbe*, Esaulova et al. reveal cell types associated with TB containment and disease progression in non-human primates, which may provide immunologic goalposts for vaccine design.
CD163⁺MRC1⁺ and CD163⁺MRC1⁺TREM2⁺ AM-like macrophages were key features of LTBI and HC. In contrast, the third population of CD163⁺MRC1⁺ low IFN-responsive macrophages were exclusively found in primates with active PTB. This latter population of CD163⁺MRC1⁺ low IFN-responsive macrophages exhibited a strong signature of response to type 1 and 2 IFNs, high expression of IFN-dependent chemokine, CXCL9-11, and expressed S100A8/9—proinflammatory proteins previously identified in the serum of active TB patients (Ahmed et al., 2020). These macrophages also express the immunosuppressive checkpoint enzyme indoleamine 2,3-dioxxygenase (IDO1), which promotes tryptophan conversion to kynurenine (Esaulova et al., 2021; Gautam et al., 2018). Therefore, these CD163⁺MRC1⁺ low macrophages are key IFN responders and express suppressive molecules. Interstitial-like CD161⁺MRC1⁻ macrophages were also identified in HC and LTBI NHPs; however, this population significantly decreased in active PTB.

Interestingly, the authors observed an increase in pDCs in the lungs of macaques with active PTB when compared with LTBI animals. This was reflected by significant depletion of peripheral pDCs in active PTB when compared with the HC or LTBI. The decrease in peripheral pDCs in macaques with active PTB is associated with significantly increased accumulation of peripheral classical monocytes when compared with HC or LTBI macaques. The authors then demonstrate that peripheral pDCs were specifically depleted in PBMCs of individuals with PTB when compared with pDCs in LTBI or HC. Together, these results describe the distinct accumulation of pDCs in the lung during active PTB disease in both macaques and humans, likely by recruitment from the periphery.

This work demonstrates that single-cell technologies validated with conventional techniques serve as powerful tools that can elucidate the complex host immune cell interactions often associated with inflammatory diseases like TB. Through this approach, Esaulova and colleagues set immunological goalposts for rational vaccine development through the identification of correlates of protection during LTBI as well as correlates of disease progression in active PTB such as IDO1 and LAG3. The identification of cell types present during contained TB suggests avenues for the development of host-directed therapies. One such avenue is targeting IDO1 or LAG3 to develop host-directed immune therapies via immune checkpoint blockade.

The application of single-cell technologies can lead to unbiased deep insight into a cell’s transcriptome, phenotype, physiology, and function, often shifting existing paradigms and expanding our knowledge of complex biological systems. This timely and pivotal study characterizing the lung landscape associated with successful containment versus disease progression during TB significantly expands our understanding of TB immunopathogenesis, and it identifies much-needed immune correlates of protection. The data from this study can provide a valuable roadmap for future TB pathogenesis research and for the rational design of more effective vaccines, immunotherapies, diagnostics, and small molecule inhibitors to control global TB.

DECLARATION OF INTERESTS

P.K.U. and W.R.B. are inventors on patents concerning recombinant BCG vaccines for TB.

REFERENCES

Ahmed, M., Thirunavukkarasu, S., Rosa, B.A., Thomas, K.A., Das, S., Rangel-Moreno, J., Lu, L., Mehra, S., Mbendi, S.K., Thackray, L.B., et al. (2020). Immune correlates of tuberculosis disease and risk translate across species. Sci Transl Med. 12, eaay0233.

Atkuri, K.R., Stevens, J.C., and Neubert, H. (2015). Mass cytometry: a highly multiplexed single-cell technology for advancing drug development. Drug Metab. Dispos. 43, 227–233.

Esaulova, E., Das, S., Singh, D.K., Choreño-Parra, J.A., Swain, A., Arthur, L., Rangel-Moreno, J., Ahmed, M., Singh, B., Gupta, A., et al. (2021). The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell Host Microbe 29, this issue, 165–178.

Gautam, U.S., Foreman, T.W., Buscan, A.N., Veatch, A.V., Alvarez, X., Adefewanti, T., Golden, N.A., Gentry, K.M., Doyle-Meyers, L.A., Russell-Lindsay, K.E., et al. (2018). In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 115, E82–E71.

Gubin, M.M., Esaulova, E., Ward, J.P., Malkova, O.N., Runci, D., Wong, P., Noguchi, T., Arthur, C.D., Meng, W., Aalpach, E., et al. (2018). High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 175, 1014–1030.e19.

Kaushal, D., Mehra, S., Didier, P.J., and Lackner, A.A. (2012). The non-human primate model of tuberculosis. J. Med. Primatol. 41, 191–201.

Kay, A.W., Strauss-Albee, D.M., and Blish, C.A. (2016). Application of Mass Cytometry (CyTOF) for Functional and Phenotypic Analysis of Natural Killer Cells. Methods Mol. Biol. 1441, 13–26.

Proserpio, V., and Mahata, B. (2016). Single-cell technologies to study the immune system. Immunology 147, 133–140.

Scanga, C.A., and Flynn, J.L. (2014). Modeling tuberculosis in nonhuman primates. Cold Spring Harb. Perspect. Med. 4, a018584.

World Health Organization (2018). Global tuberculosis report 2018. https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf.